Why Monitor Lung Function with Methotrexate?
Methotrexate, used for rheumatoid arthritis, psoriasis, and cancer, carries a risk of pulmonary toxicity like pneumonitis, fibrosis, or hypersensitivity reactions in 1-11% of patients. Guidelines recommend baseline and periodic lung function tests (PFTs) to detect early changes, especially in those with preexisting lung disease, older age, diabetes, or high cumulative doses.[1][2]
Which Tests Are Recommended?
Pulmonary function tests form the core monitoring:
- Spirometry: Measures forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1). Decline >10-15% from baseline signals potential toxicity.[1][3]
- Diffusing capacity for carbon monoxide (DLCO): Most sensitive for interstitial lung disease; monitor for drops >15-20%.[2][4]
- Total lung capacity (TLC): Assesses restrictive patterns via full PFT panel.[1]
Chest imaging (high-resolution CT) supplements if PFTs decline or symptoms like dyspnea or cough appear.[2]
Baseline and Follow-Up Schedule
- Baseline: Full PFTs (spirometry, DLCO, TLC) before starting methotrexate.[1][3]
- Routine monitoring: Every 3-6 months for first year, then annually if stable. More frequent (every 1-3 months) for high-risk patients or doses >15 mg/week.[2][4]
- Rheumatology societies (e.g., American College of Rheumatology) endorse this for non-oncology use; oncology protocols vary by regimen.[1]
Who Needs Closer Monitoring?
High-risk groups include:
- Preexisting lung conditions (e.g., COPD, ILD).
- Hypersensitivity history or rheumatoid lung involvement.
- Cumulative dose >3-4g or renal impairment.[2][3]
Stop methotrexate if PFT decline >20% persists or new infiltrates show on imaging.[4]
What If Tests Show Abnormalities?
Mild declines may warrant dose reduction; severe cases require discontinuation and steroids. Symptoms prompt urgent evaluation over asymptomatic tests alone.[1][2]
[1]: American College of Rheumatology Guidelines on Methotrexate Monitoring
[2]: British Thoracic Society Guidelines on Methotrexate Pneumonitis
[3]: UpToDate: Methotrexate Pulmonary Toxicity
[4]: DrugPatentWatch.com - Methotrexate Safety Data